HSPG2 antibody
-
- Target See all HSPG2 Antibodies
- HSPG2 (Heparan Sulfate Proteoglycan 2 (HSPG2))
-
Reactivity
- Human, Mouse, Cow, Fish, Monkey, Pig
-
Host
- Rat
-
Clonality
- Monoclonal
-
Conjugate
- This HSPG2 antibody is un-conjugated
-
Application
- Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (IF), Flow Cytometry (FACS)
- Characteristics
- This mAb specifically precipitates heterogeneous material of high MW, identified as perlecan, a major heparan-sulfate proteoglycan (HSPG) within all basement membranes and cell surfaces. It does not cross-react with laminin, fibronectin, or dermatran sulfate proteoglycan. Because of perlecan s strategic location and ability to store and protect growth factors, it has been strongly implicated in the control of tumor cell growth and metastatic behavior. Perlecan possesses angiogenic and growth-promoting attributes primarily by acting as a co-receptor for basic fibroblast growth factor (FGF-2). Suppression of perlecan causes substantial inhibition of neoplastic growth and neovascularization. Thus, perlecan is a potent inducer of neoplasm growth and angiogenesis in vivo and therapeutic interventions targeting this key modulator of tumor progression may improve neoplastic treatment.
- Purification
- Protein G affinity chromatography
- Immunogen
- A murine EHS laminin preparation was used as the immunogen for the anti-Perlecan antibody.
- Clone
- SPM255
- Isotype
- IgG2a kappa
- Top Product
- Discover our top product HSPG2 Primary Antibody
-
-
- Application Notes
-
Optimal dilution of the anti-Perlecan antibody should be determined by the researcher.
1. Staining of formalin-fixed tissues requires boiling tissue sections in 10 mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 min
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 0.5-1 μg/mL,Immunohistochemistry (FFPE): 1-2 μg/mL for 30 min at RT (1),Prediluted format : incubate for 30 min at RT (2) - Restrictions
- For Research Use only
-
- Concentration
- 0.2 mg/mL
- Buffer
- 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide
- Preservative
- Sodium azide
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C,-20 °C
- Storage Comment
- Store the anti-Perlecan antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
-
- Target
- HSPG2 (Heparan Sulfate Proteoglycan 2 (HSPG2))
- Alternative Name
- Perlecan (HSPG) (HSPG2 Products)
- Synonyms
- HSPG antibody, PLC antibody, PRCAN antibody, SJA antibody, SJS antibody, SJS1 antibody, HSPG2 antibody, AI852380 antibody, Pcn antibody, Plc antibody, per antibody, Per antibody, heparan sulfate proteoglycan 2 antibody, perlecan (heparan sulfate proteoglycan 2) antibody, HSPG2 antibody, hspg2 antibody, Hspg2 antibody
- Background
- This mAb specifically precipitates heterogeneous material of high MW, identified as perlecan, a major heparan-sulfate proteoglycan (HSPG) within all basement membranes and cell surfaces. It does not cross-react with laminin, fibronectin, or dermatran sulfate proteoglycan. Because of perlecan s strategic location and ability to store and protect growth factors, it has been strongly implicated in the control of tumor cell growth and metastatic behavior. Perlecan possesses angiogenic and growth-promoting attributes primarily by acting as a co-receptor for basic fibroblast growth factor (FGF-2). Suppression of perlecan causes substantial inhibition of neoplastic growth and neovascularization. Thus, perlecan is a potent inducer of neoplasm growth and angiogenesis in vivo and therapeutic interventions targeting this key modulator of tumor progression may improve neoplastic treatment.
- Pathways
- Glycosaminoglycan Metabolic Process, Lipid Metabolism
-